Rosacea
Niadyne Pharma research has recently shown that impairment of skin barrier integrity is a common link between the cause of certain chronic skin diseases and the failure of drugs to effectively treat such conditions. That is, a degraded skin barrier not only is a major factor in the cause of these skin diseases, but current drug treatment often aggravates these conditions by further degrading the skin barrier. A degraded skin barrier causes the skin to become irritated to the point where drug therapy is often discontinued. Moreover, drug induced skin barrier impairment often leads to a worsening of the condition sometimes causing patients to discontinue therapy or accept suboptimal results. One of Niadyne's patented molecules has been clinically proven to improve the structure and function of the skin barrier. Newly approved drugs that are the result of combining these molecules with existing drugs will not only be able to provide superior treatment in the short term, but also create changes in the skin that will likely reduce the severity or probability of the disease reoccurring Ð a common complaint with much current therapy.
Skin barrier impairment is an important factor in the cause of rosacea. Topical antibiotics now used to treat this condition provide minimal therapeutic benefit. Niadyne Pharma believes that a combination NIA-114/Metronidazole drug would provide longer lasting and more efficacious treatment for rosacea. Moreover, the improvement in skin barrier associated with the use of NIA-114 is likely to lessen the frequency of reoccurrence and the severity of this condition over time. Since it is estimated that 14 million people in the U.S. have rosacea, a drug capable of successfully treating this condition could grow this market. The current U.S. market for rosacea drugs is estimated to be $400 million per year.
